Novartis AG (VTX:NOVN) Receives Average Rating of “Hold” from Analysts

Novartis AG (VTX:NOVN) has been assigned an average rating of “Hold” from the seventeen brokerages that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is CHF 89.18.

NOVN has been the subject of a number of research analyst reports. Jefferies Financial Group set a CHF 95 target price on Novartis and gave the company a “buy” rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. set a CHF 85 target price on Novartis and gave the company a “sell” rating in a report on Wednesday, April 3rd. Credit Suisse Group set a CHF 84 target price on Novartis and gave the company a “neutral” rating in a report on Thursday, April 25th. Deutsche Bank set a CHF 85 target price on Novartis and gave the company a “neutral” rating in a report on Thursday, April 25th. Finally, HSBC set a CHF 83 price target on Novartis and gave the company a “neutral” rating in a research report on Thursday, April 25th.

Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: Trade War

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.